MASLD treatment—a shift in the paradigm is imminent
MASLD prevalence is growing towards the leading cause of end-stage liver disease. Up to today, the most effective treatment is weight loss. Weight loss interventions are moving from lifestyle changes to bariatric surgery or endoscopy, and, more recently, to a new wave of anti-obesity drugs that can...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1316284/full |
| _version_ | 1797397034274127872 |
|---|---|
| author | Mariana Verdelho Machado Mariana Verdelho Machado |
| author_facet | Mariana Verdelho Machado Mariana Verdelho Machado |
| author_sort | Mariana Verdelho Machado |
| collection | DOAJ |
| description | MASLD prevalence is growing towards the leading cause of end-stage liver disease. Up to today, the most effective treatment is weight loss. Weight loss interventions are moving from lifestyle changes to bariatric surgery or endoscopy, and, more recently, to a new wave of anti-obesity drugs that can compete with bariatric surgery. Liver-targeted therapy is a necessity for those patients who already present liver fibrosis. The field is moving fast, and in the near future, we will testify to a disruptive change in MASLD treatment, similar to the paradigm-shift that occurred for hepatitis C almost one decade ago with direct antiviral agents. |
| first_indexed | 2024-03-09T01:04:09Z |
| format | Article |
| id | doaj.art-dd5ccc0f2ac644778642986e2bebd966 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-03-09T01:04:09Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-dd5ccc0f2ac644778642986e2bebd9662023-12-11T12:14:28ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2023-12-011010.3389/fmed.2023.13162841316284MASLD treatment—a shift in the paradigm is imminentMariana Verdelho Machado0Mariana Verdelho Machado1Faculdade de Medicina, Universidade de Lisboa, Lisbon, PortugalHospital de Vila Franca de Xira, Vila Franca de Xira, PortugalMASLD prevalence is growing towards the leading cause of end-stage liver disease. Up to today, the most effective treatment is weight loss. Weight loss interventions are moving from lifestyle changes to bariatric surgery or endoscopy, and, more recently, to a new wave of anti-obesity drugs that can compete with bariatric surgery. Liver-targeted therapy is a necessity for those patients who already present liver fibrosis. The field is moving fast, and in the near future, we will testify to a disruptive change in MASLD treatment, similar to the paradigm-shift that occurred for hepatitis C almost one decade ago with direct antiviral agents.https://www.frontiersin.org/articles/10.3389/fmed.2023.1316284/fullMASLDtreatmentobesityweight lossliver disease-targeted drugs |
| spellingShingle | Mariana Verdelho Machado Mariana Verdelho Machado MASLD treatment—a shift in the paradigm is imminent Frontiers in Medicine MASLD treatment obesity weight loss liver disease-targeted drugs |
| title | MASLD treatment—a shift in the paradigm is imminent |
| title_full | MASLD treatment—a shift in the paradigm is imminent |
| title_fullStr | MASLD treatment—a shift in the paradigm is imminent |
| title_full_unstemmed | MASLD treatment—a shift in the paradigm is imminent |
| title_short | MASLD treatment—a shift in the paradigm is imminent |
| title_sort | masld treatment a shift in the paradigm is imminent |
| topic | MASLD treatment obesity weight loss liver disease-targeted drugs |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2023.1316284/full |
| work_keys_str_mv | AT marianaverdelhomachado masldtreatmentashiftintheparadigmisimminent AT marianaverdelhomachado masldtreatmentashiftintheparadigmisimminent |